Because mTOR is a regulator of aerobic glycolysis by promoting activation of glycolytic enzymes [22], we evaluated whether it was feasible to simultaneously inhibit glycolysis and mTOR activity in LKB1−/−NIC mammary tumors by treating mice daily for 21 days with low dose 2-DG (25 mgkg−1) alone, AZD8055 (20 mgkg−1) alone and 2-DG plus AZD8055 (25mgkg−1plus 20 mgkg−1). Here, STK11 is linked to breast cancer.